Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
Home / moderate to severe OSA
Browsing Tag: moderate to severe OSA
Social Icons
Featured Posts
1
AbbVie’s Boey Approved in Canada for Glabellar Lines
June 24, 20262
Roche’s Itovebi Moves Closer to Public Access in Canada
June 24, 20263
